SEC Form 4 · accession 0001857250-26-000002
Sionna Therapeutics, Inc. · SION
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Edward Fleming
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002036042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $36.73 | Jun 17, 2026 | A | 17,340 | A | — | Jun 16, 2036 | Common Stock | 17,340 | 17,340 | D |
Explanation of responses
- F1The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.
- F2This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.